p53 gene in treatment of hepatic carcinoma: Status quo

Table 3 Comparison of several characteristics of rAd-p53 with oncolytic virus products

Products	Characteristics
rAd-p53	p53 gene is transfected into HCC cells with recombinant adenoviral vector expressing wt-p53
Advexin	Larger host range, low pathogenicity to human, replication-impaired adenoviral vector carrying the p53 gene
Gendicine	The first commercial gene therapy product in the world approved by SFDA
SCH58500	Replication-deficient type 5 adenovirus vector expressing human wt-p53 under control of cytomegalovirus promoter
Oncolytic viruses	Incapable of replicating in normal cells but selectively replicating in p53-defective tumor cells to lyse them
ONYX-015	Tumor-selective replicating virus, the prototype for oncolytic adenoviral therapy
CNHK300-mE	Replication-competent with advantages of both gene and virus therapies